How to buy Orgenesis stock | $4.44

Orgenesis Inc is a biotechnology business based in the US. Orgenesis shares (ORGS) are listed on the NASDAQ and all prices are listed in US Dollars. Orgenesis employs 309 staff and has a trailing 12-month revenue of around USD$35.8 million.

How to buy shares in Orgenesis

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Orgenesis. Find the stock by name or ticker symbol: ORGS. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Orgenesis reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$4.44, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Orgenesis, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Orgenesis. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Orgenesis share price

Use our graph to track the performance of ORGS stocks over time.

Orgenesis shares at a glance

• Key figures

Information last updated 2020-12-02.

Latest market close	USD$4.44
52-week range	USD$2.35 - USD$8.2
50-day moving average	USD$4.8411
200-day moving average	USD$5.6175
Wall St. target price	USD$10
PE ratio	1.9463
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$2.348

Buy Orgenesis shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Orgenesis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Orgenesis Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Orgenesis price performance over time

Historical closes compared with the close of $4.44 from 2020-12-09

1 week (2021-01-07)	-9.20%
1 month (2020-12-17)	-5.73%
3 months (2020-10-16)	-10.12%
6 months (2020-07-16)	-23.18%

1 year (2020-01-16)	-11.55%
2 years (2019-01-16)	-13.45%
3 years (2018-01-16)	6.4
5 years (2016-01-15)	1,245.45%

Is Orgenesis under- or over-valued?

Valuing Orgenesis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Orgenesis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Orgenesis's P/E ratio

Orgenesis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Orgenesis shares trade at around 2x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Orgenesis financials

Revenue TTM	USD$35.8 million
Gross profit TTM	USD$15 million
Return on assets TTM	-15.09%
Return on equity TTM	0%
Profit margin	130.23%
Book value	$3.922
Market capitalisation	USD$110.4 million

TTM: trailing 12 months

Shorting Orgenesis shares

There are currently 381,977 Orgenesis shares held short by investors – that's known as Orgenesis's "short interest". This figure is 0.2% down from 382,727 last month.

There are a few different ways that this level of interest in shorting Orgenesis shares can be evaluated.

Orgenesis's "short interest ratio" (SIR)

Orgenesis's "short interest ratio" (SIR) is the quantity of Orgenesis shares currently shorted divided by the average quantity of Orgenesis shares traded daily (recently around 33624.735915493). Orgenesis's SIR currently stands at 11.36. In other words for every 100,000 Orgenesis shares traded daily on the market, roughly 11360 shares are currently held short.

However Orgenesis's short interest can also be evaluated against the total number of Orgenesis shares, or, against the total number of tradable Orgenesis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Orgenesis's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Orgenesis shares in existence, roughly 20 shares are currently held short) or 0.0172% of the tradable shares (for every 100,000 tradable Orgenesis shares, roughly 17 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Orgenesis.

Find out more about how you can short Orgenesis stock.

Orgenesis share dividends

We're not expecting Orgenesis to pay a dividend over the next 12 months.

Have Orgenesis's shares ever split?

Orgenesis's shares were split on a 1:12 basis on 16 November 2017. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Orgenesis shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Orgenesis shares which in turn could have impacted Orgenesis's share price.

Orgenesis share price volatility

Over the last 12 months, Orgenesis's shares have ranged in value from as little as $2.35 up to $8.2. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Orgenesis's is 1.3703. This would suggest that Orgenesis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Orgenesis overview

Orgenesis Inc. offers biotechnology solutions focusing on cell and gene therapies (CGTs). The company's Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on identification of new therapies and leverages its POCare platform to provide a pathway for these therapies to treat patients. Additionally, the company's Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies. Orgenesis Inc. was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. The company was founded in 2008 and is based in Germantown, Maryland.

Frequently asked questions

• What percentage of Orgenesis is owned by insiders or institutions?

  Currently 13.123% of Orgenesis shares are held by insiders and 26.418% by institutions.

• How many people work for Orgenesis?

  Latest data suggests 309 work at Orgenesis.

• When does the fiscal year end for Orgenesis?

  Orgenesis's fiscal year ends in November.

• Where is Orgenesis based?

  Orgenesis's address is: 20271 Goldenrod Lane, Germantown, MD, United States, 20876

• What is Orgenesis's ISIN number?

  Orgenesis's international securities identification number is: US68619K2042

• What is Orgenesis's CUSIP number?

  Orgenesis's Committee on Uniform Securities Identification Procedures number is: 68619K105